In the present study, we investigated the effect of the antiestrogen compound tamoxifen on BK channels by the use of the patch-clamp technique. The perfusion of 10 nM tamoxifen significantly increased the magnitude of a voltage-dependent K ϩ current by 22.6 Ϯ 10.6% (n ϭ 23). The effect of tamoxifen was always obtained in the first minute, peaked at 5.9 Ϯ 2.2 min (n ϭ 23), and was abolished by the perfusion of tetraethylammonium (0.5 mM), charybdotoxin (50 nM), or iberiotoxin (100 nM). The stimulatory effect of 10 nM tamoxifen was the same at low (50 nM) and high (700 nM) internal calcium concentration and was not additive to that of 17--estradiol (E 2 ) or its membrane-impermeant form, -estradiol 6-(O-carboxymethyl)-oxime:bovine serum albumin. Furthermore, the effect of tamoxifen was still recorded in the presence of the selective estrogen receptor antagonist faslodex (ICI-182,780; 1 M). At the singlechannel level, tamoxifen significantly increased the open probability of the BK channel by 46.2 Ϯ 10.1% (n ϭ 4) without changing its unitary conductance. Moreover, we show here that the stimulation of BK channel activity by tamoxifen is involved in MCF-7 cell proliferation. Taken together, these results permitted us to identify the BK channel as the molecular target of tamoxifen that probably acts at the same extracellular molecular level as E 2 . The site of action of tamoxifen is probably the channel itself or the auxiliary  subunits.Breast cancer is generally believed to arise when dividing cells undergo mutations, and these genetically damaged cells become susceptible to unrestrained division. Thus, female hormones and other hormones that affect growth of the mammary gland are potential risk factors for breast cancer. In contrast, factors that induce differentiation in the mammary gland, such as pregnancy and lactation, are likely to reduce the risk of breast cancer. In the case of breast cancer, estrogens are still one of the most important risk factors. Indeed, whereas 17--estradiol (E 2 ) is a key growth regulator in the normal mammary gland, clinical and experimental data have clearly established that exposure to this steroid hormone is also the leading cause of sporadic female breast cancer. Thus, the usefulness of antiestrogens and/or chemopreventives is closely associated with antagonizing the activity of E 2 . The fact that estrogens may affect carcinogenesis by acting either as initiators (i.e., directly damage DNA; Liehr and Ricci, 1996) or as promoters (i.e., promoting the growth and/or survival of initiated cells; ESHRE Capri Workshop, 2004;Veronesi et al., 2005) has justified the use of antiestrogenic compounds such as tamoxifen in estrogenic hormone replacement therapy. However, in addition to their key role in female reproductive functions, estrogens have beneficial effects on unrelated tissues, as demonstrated by the effects of hormone replacement therapy on postmenopausal women (Mitlack and Cohen, 1997;Cosman and Lindsay, 1999). Indeed, estrogens can prevent osteoporosis by inhibitin...